HR
MDGL icon

Howe & Rusling’s Madrigal Pharmaceuticals MDGL Stock Holding History

Howe & Rusling’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,235
Closed -$106K – 854
2019
Q3 		$106K Hold
1,235
– – 0.02% 237
2019
Q2 		$129K Hold
1,235
– – 0.02% 224
2019
Q1 		$155K Buy
+1,235
New +$154K 0.03% 202
2014
Q2 		– Sell
-180
Closed -$27K – 891
2014
Q1 		$27K Buy
+180
New +$35.5K 0.01% 411
2013
Q3 		– Sell
-180
Closed -$31K – 911
2013
Q2 		$31K Buy
+180
New +$46.9K 0.01% 419

Other funds holding MDGL

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Howe & Rusling's MDGL Position: Q4 2019 in Review

Howe & Rusling sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2019, closing a stake of 1,235 shares — an estimated $106K sold.

Howe & Rusling first reported a position in MDGL in Q2 2013 and held it in 5 quarters. The position peaked at $155K in Q1 2019. 120 funds tracked by Wall St. Rank hold MDGL as of Q4 2019.

  • Howe & Rusling reported no remaining Madrigal Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Howe & Rusling sold 1,235 Madrigal Pharmaceuticals shares in Q4 2019, an estimated $106K.
  • Howe & Rusling first reported a position in Madrigal Pharmaceuticals in Q2 2013 and held it in 5 quarters.
  • Howe & Rusling's Madrigal Pharmaceuticals position peaked at $155K in Q1 2019.
  • 120 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2019.

Based on Howe & Rusling's 13F filing for Q4 2019, filed 5 Feb 2020.